SG/PUT/VERTEX PHARMACEUTICALS/500/0.1/20.09.24

SG/PUT/VERTEX PHARMACEUTICALS/500/0.1/20.09.24 Share Price

DE000SY18W79

Market Closed - Bid/Ask 11:57:47 03/07/2024 am IST			After market 11:43:02 pm
3.32 ^EUR	-7.78%		3.63	+9.34%

Current month

+5.57%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart SG/PUT/VERTEX PHARMACEUTICALS/500/0.1/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	02/07	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	02/07	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	02/07	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	02/07	CI

More news

Quotes 5-day view

Date	Price	Change
03/24/03	3.32	-7.78%
02/24/02	3.6	-1.37%
01/24/01	3.65	+7.04%
28/24/28	3.41	+3.33%
27/24/27	3.3	-5.98%

Delayed Quote Börse Stuttgart

Last update July 03, 2024 at 11:57 am IST

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Société Générale
WKN	SY18W7
ISIN	DE000SY18W79
Date issued	25/06/2024
Strike	500 $
Maturity	20/09/2024 (79 Days)
Parity	10 : 1
Emission price	3.92 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	3.65 €
Lowest since issue	3.2 €
Delta	-0.62x
Omega	7.417
Premium	2.05x
Gearing	11.95x
Moneyness	1.063
Difference Strike	29.72 $
Difference Strike %	+5.94%
Spread	0.26 €
Spread %	6.88%
Theoretical value	3.630
Implied Volatility	28.33 %
Total Loss Probability	32.86 %
Intrinsic value	2.757
Present value	0.8732
Break even	460.87 €
Theta	-0.07x
Vega	0.08x
Rho	-0.07x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

473.8 USD

Average target price

468.3 USD

Spread / Average Target

-1.16%

Consensus